Company intelligence / Profile preview
MicroQuin
United Kingdommicroquin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MicroQuin has developed a first-in-class small molecule therapeutic that targets TMBIM6, an intracellular environment regulator activated in cancer cells. Preclinical results show the drug induces rapid death of cancer cells across multiple tumor types while sparing healthy cells. The approach is also being explored for neurodegenerative and traumatic brain injury indications based on findings from space-based research using 3D cell cultures on the International Space Station.
- Therapeutic areas
- OncologyEndocrinologyNeurologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
International Space Station National Laboratory/ISS Natural LaboratoryBioServe Space Technologies
Beyond the preview
Go deeper on MicroQuin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroQuin.